Literature DB >> 11831591

The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients.

S Simic-Ogrizovic1, G Backus, A Mayer, J Vienken, L Djukanovic, W Kleophas.   

Abstract

In recent years the percentage of diabetic patients on haemodialysis has increased. Considering the high frequency of intradialytic hypotensive and hypoglycaemic episodes experienced by these patients, it was the aim of the present study to evaluate the influence of different dialysate glucose concentrations (5.5 mmol/L or 11 mmol/L) on blood pressure and glycaemic regulation, using special dialysis equipment - the GENIUS System. This cross-over, prospective and randomised study, total duration 14 weeks, included 20 diabetic patients on maintenance haemodialysis. Group 1: 9 patients dialysed using dialysate with a glucose concentration of 5.5 mmol/L and after 7 weeks switched to dialysate with a glucose concentration of 11 mmol/L. Group 2: vice versa. Results show a statistically higher number of patients with hypoglycaemic and hypotensive episodes using dialysate with a 5.5 mmol/L glucose concentration. Also, mean serum glucose values were higher during haemodialysis sessions with a glucose dialysate concentration of 11 mmol/L. There were no statistical differences between the groups in laboratory values, HbA1C, insulin doses or in anthropometric parameters. Our results suggest that fewer diabetic patients undergoing haemodialysis using a higher dialysate glucose concentration of 11 mmol/L have hypoglycaemic and hypotensive episodes. Since this dialysate glucose concentration had no influence on lipid or hepatic metabolism, anthropometric parameters and especially HbA/1C values in this short-term study, the long term examination of its effects is warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11831591

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  7 in total

1.  Sodium removal and plasma tonicity balance are not different in hemodialysis and hemodiafiltration using high-flux membranes.

Authors:  Vincenzo La Milia; Chiara Ravasi; Fabio Carfagna; Elena Alberghini; Ivano Baragetti; Laura Buzzi; Francesca Ferrario; Silvia Furiani; Gaia Santagostino Barbone; Giuseppe Pontoriero
Journal:  J Nephrol       Date:  2019-01-10       Impact factor: 3.902

Review 2.  Haemodialysis-induced hypoglycaemia and glycaemic disarrays.

Authors:  Masanori Abe; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2015-04-07       Impact factor: 28.314

3.  Association of Predialysis Calculated Plasma Osmolarity With Intradialytic Blood Pressure Decline.

Authors:  Finnian R Mc Causland; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2015-05-12       Impact factor: 8.860

Review 4.  Diets and enteral supplements for improving outcomes in chronic kidney disease.

Authors:  Kamyar Kalantar-Zadeh; Noël J Cano; Klemens Budde; Charles Chazot; Csaba P Kovesdy; Robert H Mak; Rajnish Mehrotra; Dominic S Raj; Ashwini R Sehgal; Peter Stenvinkel; T Alp Ikizler
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

5.  Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: A national cohort study.

Authors:  Yeh-Wen Chu; Hsuan-Ming Lin; Jhi-Joung Wang; Shih-Feng Weng; Chih-Ching Lin; Chih-Chiang Chien
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

Review 6.  Optimizing haemodialysate composition.

Authors:  Francesco Locatelli; Vincenzo La Milia; Leano Violo; Lucia Del Vecchio; Salvatore Di Filippo
Journal:  Clin Kidney J       Date:  2015-08-08

7.  Analysis of the metabolic properties of maintenance hemodialysis patients with glucose-added dialysis based on high performance liquid chromatography quadrupole time-of-flight mass spectrometry.

Authors:  Li Cui; Yu Meng; Dan Xu; Yanyan Feng; Gangyi Chen; Bo Hu; Guijuan Feng; Lianghong Yin
Journal:  Ther Clin Risk Manag       Date:  2013-10-29       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.